The Effects of Insulin-Like Growth Factor-I (IGF-I) and the Idea of Replacement Therapy in the Healthy Elderly Individuals to Improve Quality of Life Standards both Physically and Mentally

Abstract

One significant molecule that has sparked a lot of interest in gerontology is insulin-like growth factor-I (IGF-I). The connection between IGF-I and the replacement therapy has been the center for many investigations for the past decade. Age-related decline in bodily functions is thought to be accompanied by a decline in IGF-I levels, which fall with growing age. As adults age, there is a reduction in the concentration of IGF-I. This decline in both growth hormone (GH) and IGF-I, as it is evident in aged adults may be associated with increased body fat, reduced muscle strength, decreased bone mass, reduced lean body mass, and ultimately may lead to many aged, related diseases. This decline of IGF-I may lead to a decrease of overall body performance and thus may decrease the quality of life. In the current review, we looked at the prior history of the pertinent articles to discover a perception that would help us get close to the concept of the therapeutic step and give a perspective on a potential IGF-I replacement therapy in healthy older subjects. In more detail, this review will list and explain the advantages and disadvantages of the IGF-I system's impact on the aged organ systems. In addition, we aim to discuss the general functional properties of IGF-I and implications of its possible use as a replacement to the healthy elderly subjects to improve their quality-of-life standards both physically and mentally and we will emphasis its downfalls and new perceptions.